ロード中...
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
Bortezomib inhibits nuclear factor-κB (NF-κB). Cetuximab is a chimeric mouse–human antibody targeted against epidermal growth factor receptor (EGFR). We hypothesised that concomitant blockade of NF-κB and EGFR signalling would overcome EGFR-mediated resistance to single-agent bortezomib and induce a...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2694419/ https://ncbi.nlm.nih.gov/pubmed/19401697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605043 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|